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Abstract: To improve the prognosis of glioblastoma, we developed an adjuvant treatment 
directed to a neglected aspect of glioblastoma growth, the contribution of nonmalignant mono-
cyte lineage cells (MLCs) (monocyte, macrophage, microglia, dendritic cells) that infiltrated 
a main tumor mass. These nonmalignant cells contribute to glioblastoma growth and tumor 
homeostasis. MLCs comprise of approximately 10%–30% of glioblastoma by volume. After 
integration into the tumor mass, these become polarized toward an M2 immunosuppressive, 
pro-angiogenic phenotype that promotes continued tumor growth. Glioblastoma cells initiate 
and promote this process by synthesizing 13 kDa MCP-1 that attracts circulating monocytes to 
the tumor. Infiltrating monocytes, after polarizing toward an M2 phenotype, synthesize more 
MCP-1, forming an amplification loop. Three noncytotoxic drugs, an antibiotic – minocycline, 
an antihypertensive drug – telmisartan, and a bisphosphonate – zoledronic acid, have ancillary 
attributes of MCP-1 synthesis inhibition and could be re-purposed, singly or in combination, to 
inhibit or reverse MLC-mediated immunosuppression, angiogenesis, and other growth-enhancing 
aspects. Minocycline, telmisartan, and zoledronic acid – the MTZ Regimen – have low-toxicity 
profiles and could be added to standard radiotherapy and temozolomide. Re-purposing older 
drugs has advantages of established safety and low drug cost. Four core observations support 
this approach: 1) malignant glioblastoma cells require a reciprocal trophic relationship with 
nonmalignant macrophages or microglia to thrive; 2) glioblastoma cells secrete MCP-1 to 
start the cycle, attracting MLCs, which subsequently also secrete MCP-1 perpetuating the 
recruitment cycle; 3) increasing cytokine levels in the tumor environment generate further 
immunosuppression and tumor growth; and 4) MTZ regimen may impede MCP-1-driven 
processes, thereby interfering with glioblastoma growth.
Keywords: cognition-sparing, high-grade glioma, immunosuppression, macrophage, microglia, 
monocyte
Introduction
Re-purposing of older, already-marketed drugs is not a new concept. With technological 
advances giving us a greater understanding of molecular pathways in cancer cells, 
the idea of re-purposing (redirecting, repositioning, etc) a previously approved drug, 
with a known safety/toxicity profile for lower cost, risk, and time, compared with 
developing novel pharmaceuticals has appeal.1–4
Our paper represents a contribution to the ongoing efforts in developing treatments 
for glioblastoma, one of the most treatment-refractory of all human cancers. Challenges 
to treatment include difficulty in drug delivery across the blood–brain barrier, the wide 
heterogeneity of glioblastoma cells within individual tumors,5–7 and the multiplic-
ity of essential signaling and metabolic pathways within individual tumor cells, the 
so-called “Nile Distributary Problem”.4,8 One area of growing interest is modifying 
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tumor–immune system signaling pathways, specifically the 
cross talk between the tumor cells and the immune cells resi-
dent in the tumor microenvironment including monocytes, 
dendritic cells, macrophages, and microglia, collectively 
termed monocyte lineage cells (MLCs).
Early in development, the embryonic brain becomes 
populated by bone marrow-derived MLCs, to finally com-
prise ~10%–20% of the adult brain, appearing as microglia. 
Circulating marrow-derived monocytes can also populate an 
adult brain, particularly during pathological states, including 
glioblastoma, but also in the setting of infection, trauma, or 
inflammatory disease such as multiple sclerosis, appearing 
then in brain as either macrophages or microglia (described 
in the magisterial review of microglia by Harry9). Some of 
the first micrographs of microglia by Klatzo from 1952 have 
not been surpassed.10 Although normal steady-state microglia 
have been called “quiescent”, they are in fact physiologically 
active in multiple homeostatic roles essential to brain function 
by scavenging dead cell remnants, phagocytosis, antigen 
presentation, synaptic maintenance, neurite pruning, repair 
and angiogenesis, and extracellular signaling.11,12 Microglia 
are in continuous reciprocal humoral communication with 
nearby neurons and astrocytes. Importantly for understanding 
glioblastoma, microglia are normally sessile but become 
motile on activation.
MLCs, including microglia, have activation states termed 
M1 or M2, but these might be better viewed as spectral 
extremes. The M1-phenotype is associated with high levels 
of cytokine interleukin (IL)-1beta, IL-12, IL-23, TNF-alpha, 
nitric oxide synthase, CD40, MHC I, and MHC II expression; 
these M1 cells are traditionally called pro-inflammatory state/
activated microglia. In contrast, M2 cells have low levels of 
these inflammatory mediators, are profibrotic, synthesize 
transforming growth factor-beta and IL-10, tend to suppress 
inflammation, and promote neovascularization.11,12 In relation 
to cancer, the M1 phenotype functions more in an immune-
boosting/antitumor role, whereas the M2 phenotype is more 
anti-inflammatory and tumor-supportive.
The critical importance of this tumor–microglia rela-
tionship to tumor growth has been observed in a number 
of recent papers.12–17 Furthermore, this ongoing “reciprocal 
supportive interplay”17 facilitates more than just enhanced 
vigor of tumor cell division and enhanced blood supply 
but potentially also contributes to glioblastoma migra-
tory invasion into the surrounding brain.18 Hewedi et al 
recognize “glioblastoma therapies should address this key 
CD68-positive [ie, monocyte/macrophage] population”.19 
We propose targeting MCP-1, a 13 kDa signaling peptide, 
synonymous with CC-chemokine ligand 2, which binds to 
outer cell membrane receptors CCR2 and/or CCR4 on MLCs 
and facilitates glioblastoma–microglia interaction.
This paper reviews and extends this concept, fills in 
details, and draws the following simple and straightforward 
conclusions:
a) The “reactive gliosis”20 seen involved with and surrounding 
the main glioblastoma tumor mass is not an epiphenom-
enon but rather is a crucial core element of glioblastoma 
pathology.
b) It is primarily the malignant glioblastoma cell that gener-
ates pathological signals, including MCP-1, to systemic 
monocytes/microglia.
c) Otherwise normal but pathologically activated MLCs are 
important for robust glioblastoma cell growth; these cells 
are attracted by increased MCP-1 signaling within the 
tumor mass. MCP-1 is also an important signal for pre-
ferred MLC differentiation to the M2 anti-inflammatory/
tumor-promoting phenotype.
d) These tumor-infiltrating and pathologically functioning 
MLCs contribute to a feedback loop involving MCP-1 
secretion which further perpetuates glioblastoma produc-
tion of MCP-1.
e) MCP-1 represents a critical mechanism of tumor–microglia 
communication which contributes significantly to tum-
origenesis and potential invasion and is a potential 
therapeutic target.
f) Three noncytotoxic drugs, minocycline, telmisartan, and 
zoledronic acid, the MTZ Regimen, are all approved for 
use in humans for noncancer conditions, are all lipophilic 
and highly brain-penetrant, are all capable of targeting the 
pathologic MCP-1 secretion, and together will provide 
MCP-1 and consequently MLC-focused treatment.
A well-developed research database supports each of the 
three MTZ Regimen drugs’ ability to block or reduce MCP-1 
signaling and thus MLC trophic functions and pathologic 
activation. Additionally, each of these drugs is relatively 
nontoxic in humans, with significant post-marketing data 
available, and does not appear to have significant drug–
drug interactions alone or in combination. We propose this 
approach either alone or in combination with other anticancer 
therapies as a novel glioblastoma treatment approach.
Glioblastoma are heavily infiltrated 
by blood monocytes
Glioblastomas are heavily infiltrated by cells of the immune 
system, and these cells are pathophysiologically active. In 
his seminal 1952 paper describing glioblastoma histology, 
Klatzo observed, “In the majority of tumors studied there 
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Toward a noncytotoxic glioblastoma therapy
infrequently seen”.10 We have more recently come to under-
stand that these immune cell populations are composed 
of bone marrow-origin monocytes,21,22 monocyte-derived 
macrophages, and microglia,19,23–29 and neutrophils.21,30–35 
Estimates vary that these bone marrow-derived cells or 
nonmalignant microglia comprise 10%–30% of the total 
glioblastoma tumor mass,12,23,26,36,37 but there is general agree-
ment that MLCs make up a considerable percent of total 
mass38 and MLCs have an established role in glioblastoma 
growth.39 The monocyte-related component arrives both by 
migration of circulating monocytes/macrophages27 and by 
mitoses or centripetal migration of brain-resident microglia40 
and monocytes.38
Reactive gliosis in brain tissue adjacent to a growing 
glioblastoma20 is not an incidental finding or epiphenomenon. 
Reactive gliosis is rather an integral feature of glioblastoma 
and a crucial link in glioblastoma’s growth.20 Brain-resident 
microglia infiltrate and become integrated with malignant 
glioblastoma cells41 as do circulating MLCs.
M1 versus M2 phenotypes
Macrophages can be divided into M1 and M2 subtypes, 
which have contrasting activity. M1 macrophages are 
traditionally thought of as immunostimulatory with potential 
antitumor activity, whereas M2 exhibit an immunosuppres-
sive phenotype with tumor-promoting and angiotrophic 
activity.17 Human glioblastomas are richly infiltrated by 
MLCs expressing both M1 and M2 markers.14,24 Although 
some studies indicate that these MLCs are more of M2 
immunosuppressive, tumor trophic class,26 other studies show 
that these tissue macrophages are of indeterminate class, 
with some having attributes of both M1 and M2 phenotypes, 
whereas others have attributes of neither phenotype.24,42
Furthermore, these M1/M2 phenotypes are not terminally 
differentiated cells; in glioblastoma cell-conditioned culture 
medium, M1 macrophages can be induced to transform to 
an M2 phenotype,43 a finding that was later independently 
confirmed.28 A differentiation to M2-phenotypic macrophages 
has also recently been described to be promoted by glioma 
cell-derived extracellular vesicles.44
In another set of experiments, it has been shown that 
doxycycline (chemically similar, but more hydrophilic and 
less brain-penetrant compared with minocycline) inhibits 
M2-type polarization of human and bone marrow-derived 
mouse macrophages.45 Clearly in viral infections of the 
brain, for example, West Nile virus, circulating monocytes 
are recruited to brain tissue by virus-mediated increases 




“Gliomas attract brain-resident (microglia) and peripheral 
macrophages and reprogram these cells into immunosuppres-
sive, proinvasive cells.”40 Myeloid cell infiltration and the 
function changes induced in them after contact with or prox-
imity to malignant glioblastoma cells form a central element 
of the otherwise unexplained immunosuppression common 
in glioblastoma patients.22,32,34,47,48 Of particular note, normal 
human monocytes exposed in vitro to glioblastoma cells take 
on an immunosuppressive M2 phenotype, synthesizing IL-10 
and transforming growth factor-beta.49,50
The MCP-1 amplification loop
MCP-1 agonism at CCR2 stimulates migration of monocytes/
macrophages. Glioblastoma cells themselves synthesize and 
release MCP-1.51,52 While MCP-1 remains important in MLC 
recruitment and M2 phenotype promotion, there are other 
molecules which appear to contribute to these processes as 
well. One molecule that appears to be primarily secreted from 
the stem cell subpopulation of glioblastoma cells is periostin, 
which contributes to M2 differentiation.27 Several other 
studies have demonstrated that malignant glioblastoma cells 
will also synthesize and secrete granulocyte–macrophage 
colony-stimulating factor that can also drive transformation 
from M1 to M2 tumor-infiltrating MLCs.40 That said, while 
it is difficult to compare relative contributions of different 
molecules having similar effects, it appears that MCP-1 
encompasses MLC recruiting, M2 transformation, and 
generation of a positive feedback loop to the glioblastoma 
tumor cells, while the others promote only portions of the 
larger process. Brain-resident microglia have been shown 
to migrate into a growing glioblastoma tumor; this migra-
tion is driven in part by granulocyte–macrophage colony-
stimulating factor synthesized by glioblastoma malignant 
cells themselves,40,53–58 and in part by MCP-1 synthesized 
by other already-resident microglia.
An oddity of human glioblastoma tissue is that it attracts 
immunosuppressive, regulatory T-cells (Tregs).59 Tregs 
express CCR2 receptors and are tropic along an increasing 
MCP-1 gradient.59 Glioma cell lines D-54, U-87, U-251, 
and LN-229 synthesize large amounts of MCP-1 that was 
shown to be chemotactic to Tregs.60 Glioblastoma patients 
with higher circulating plasma MCP-1 titers have a poorer 
prognosis and faster disease course compared to patients with 
low plasma titers.61 Human glioblastoma biopsy tissue over-
expresses MCP-1.62 Glioblastoma cell lines overexpressing 
































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





Having established the likely importance of MCP-1 in 
macrophages’ promotion of glioblastoma growth, the next 
section discusses how several currently marketed noncyto-
toxic drugs can defeat this growth-facilitating aspect.
Resident peritumoral microglia secrete ample MCP-1 
which in turn is chemotactic for circulating monocytes, 
thereby recruiting yet more MLCs. Thus, MCP-1 synthesis 
by glioblastoma-resident macrophages/microglia forms 
a positive amplification loop.62 Since glioblastoma cells 
themselves express MCP-1 receptors, MCP-1 mRNA, and 
MCP-1 protein,62–65 they thereby initiate this pathological 
amplification loop. Wurdinger et al rhetorically wonder 
“how to break [this] vicious cycle […] the interactive pro-
cess between glioma cells and microglia and macrophages 
[…]?”66 The MTZ Regimen now attempts to simply answer 
that question (Figure 1).
Preclinical experiments pointed to tumor-associated 
macrophages as a primary mediator of escape from antiangio-
genic therapies and prompted a study of the consequences of 
anti-VEGF monoclonal antibody bevacizumab treatment of 
recurrent glioblastoma.67 They found on autopsy that patients 
treated with bevacizumab had greatly increased numbers of 
glioblastoma tissue macrophages compared with those not 
exposed to bevacizumab.67 Of particular note to our intended 
use of macrophage-directed treatment, Lu-Emerson et al also 
found that extent of tumor infiltration with macrophages 
correlated with shorter overall survival.67
The drugs
Minocycline
Minocycline is a 457 Da, intermediate-half-life (10–20 hours), 
lipophilic, tetracycline class antibiotic68–70 with excellent 
blood–brain penetration and brain tissue levels.71 Mino-
cycline is active against a variety of Gram-positive and 
Gram-negative bacteria, Rickettsia, Chlamydia, as well as 
protozoans Plasmodia, Toxoplasma, and others.71 As an aside, 
significant neuroprotective attributes of minocycline have 
been the subject of dozens of reports in the last few years, this 
observation may provide future directions for research.72
In culture, normal microglia and glioma cell lines 
secreted ample MCP-1 which could be inhibited by 25 µM 
minocycline.73 Lipopolysaccharide-stimulated MCP-1 
protein production in monocytes was suppressed by mino-
cycline in vitro by inhibition of an IkB phosphorylation step, 
keeping NFkB within cytoplasm.74 The related tetracycline 
class antibiotic doxycycline inhibited M2 polarization in a 
laser injury model of choroidal neovascularization.45
MCP-1 levels are elevated in human Japanese enceph-
alitis-infected tissues from humans and experimentally 
infected animals.75 Correspondingly, high tissue infiltration 
of monocytes is seen, a process that can be suppressed by 
minocycline.75 Simian immunodeficiency virus-infected 
macaques had grossly upregulated cerebral MCP-1 and 
monocyte infiltration that were both partially but signifi-
cantly mitigated by minocycline.76 Ex vivo West Nile Virus 
Figure 1 MCP-1 driven, positive feedback loop between glioblastoma and MLCs.
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Toward a noncytotoxic glioblastoma therapy
exposure stimulates microglia to synthesize several cytokines, 
including MCP-1. This finding was shown to be inhibited 
by minocycline.77 Retinal ischemia–reperfusion injury and 
cell death was not prevented by minocycline, but the injury-
associated centripetal migration of monocytes/macrophages 
and increase in MCP-1 both were abrogated.78
Empirical preclinical studies of minocycline in glioma 
models have provided evidence of benefit. Growth and 
core tumor hypoxia of the gliosarcoma line 9L was inhib-
ited by minocycline by unclear means.79 Weingart et al 
found that systemically administered minocycline did not 
extend survival of 9L gliosarcoma-implanted rats but local 
delivery after primary resection did,80,81 findings confirmed 
by others in 2014.82 Growth of C6 gliomas was inhibited 
by minocycline.83 An experimental alkylating drug was 
more effective in killing C6 orthotropic transplants when 
minocycline was given concomitantly.84 Minocycline alone 
inhibited growth in an orthotropic murine glioma model.85 
U-87 glioma orthotropic transplants in nude mice grew 
slower when mice were given intraperitoneal minocycline. 
GL261 murine glioma cells grew slower in syngeneic mice 
when intraperitoneal minocycline was given.29
Two clinical studies are in progress, NCT01580969, a 
Phase II study using minocycline and bevacizumab with 
radiation for recurrent glioblastoma, and NCT02272270, a 
Phase I study adding minocycline to standard Stupp Protocol 
(temozolomide and radiation) for initial post-resection treat-
ment of primary glioblastoma.
Side effects
Skin and other structures can become hyperpigmented after 
cumulative doses exceed 100 g or duration .1 year.86 Auto-
immune disturbances such as serum sickness-like disease, 
drug-induced lupus, and autoimmune hepatitis occur but 
are rare.87 Autoimmune reactions tend not to occur until 
after .2 years of use.88
Telmisartan
Telmisartan is a brain-penetrant, highly lipophilic, 515 Da, 
intermediate-half-life (~24 hours) angiotensin II receptor 
blocker marketed to treat high blood pressure.89
Telmisartan profoundly downregulated fibronectin 
mRNA and suppressed MCP-1 over-synthesis in kidneys 
after experimental unilateral ureter obstruction.90 In 
similar fashion, telmisartan decreased elevated MCP-1 and 
fibronectin associated with diabetic kidneys.91
Cerebral MCP-1 increases with age in spontaneously 
hypertensive stroke-resistant rats well beyond the minimal 
increases seen in normotensive rats as they age. Low-dose 
telmisartan (in doses low enough to not alter hypertension) 
diminished this progressive increase in cerebral MCP-1 immu-
nohistochemical staining in these spontaneously hypertensive 
rats with normal aging.92,93 In other experiments, telmisartan 
given in higher doses to normalize these rats’ blood pressure 
lowered cerebral MCP-1 even further.92,93 Exposure to homo-
cysteine increased levels of MCP-1 mRNA in, and consequent 
monocyte binding to, human umbilical vein endothelial 
cells, an effect blocked by telmisartan and other peroxisome 
proliferator-activated receptor (PPAR)-gamma agonists.94
Hepatic MCP-1 and macrophage infiltration into diet-
induced steatohepatitis in susceptible mice was inhibited by 
telmisartan.95 Telmisartan diminished macrophage popula-
tion, MCP-1 protein, and CCR2 expression in the aorta of 
spontaneously hypertensive rats.96 It also lowered serum 
MCP-1 level.96
Hypertensive humans with increased carotid intima-
media thickness had increased serum MCP-1 (thought to 
contribute to the carotid inflammatory atherosclerotic pro-
cess) that diminished under telmisartan treatment.97 However, 
although confirming that hypertensive patients had elevated 
circulating MCP-1, others found no decrease in MCP-1 after 
successful telmisartan lowering of their blood pressure.98 
Tumor-infiltrating monocytes/macrophages, as defined by 
leukocytes that were CD14 and CD68 positive, are known to 
heavily infiltrate inflammatory breast cancer tissue.99 These 
monocytes/macrophages secreted significant amounts of 
MCP-199 forming thereby a macrophage amplification circuit 
that as we indicate here is also operative in glioblastoma. 
Telmisartan attenuated the elevated myocardial MCP-1 in 
streptozotocin diabetic rats.100 Telmisartan decreased MCP-1 
mRNA in tumor necrosis factor-alpha-stimulated human 
umbilical vein endothelial cells.101
Ex vivo lipopolysaccharide-stimulated circulating human 
monocytes secreted MCP-1 and other inflammation mediators 
that were decreased by co-incubation with telmisartan.102,103 
Otherwise normal people with arterial hypertension treated 
with telmisartan exhibited lowered gene expression of both 
MCP-1 and PPAR-gamma in circulating monocytes com-
pared to pretreatment levels.104 In other in vitro experiments, 
patients with essential hypertension treated for 3 months with 
telmisartan exhibited reduced circulating monocyte MCP-1 
mRNA compared to their pretreatment starting values.104
Angiotensin II signals via angiotensin 1 receptors. 
Angiotensin II binding to angiotensin 1 receptors induces 
rat glomerular endothelia to increase synthesis of MCP-1.105 
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Zoledronic acid is a long-half-life, 272 Da bisphosphonate, 
that although not a low-side effect drug,106 has seen increasing 
use as treatment adjuvant in a variety of cancers.107 Bispho-
sphonate drugs are commonly known and clinically used 
for inhibition of osteoclast activity with consequent reduc-
tion in bone resorption. Zoledronic acid use in advanced 
cancer patients has been shown to reduce bone events and 
hypercalcemia.107,108 Zoledronic acid depressed normal osteo-
blast secretion of MCP-1.109
In human osteosarcoma, tumor growth directly correlates 
with and occurs commensurately with osteoclast activa-
tion with corresponding osteolysis. Both cell line and 
human osteosarcomas secrete MCP-1 that forms one of the 
osteoclast-stimulating paths. Zoledronic acid inhibits both 
synthesis and secretion of osteosarcoma MCP-1 with con-
sequent diminution of peritumoral osteoclast activity.110 Of 
particular note to our thinking about glioblastoma, zoledronic 
acid inhibition of macrophage/osteoclast function reduced 
growth of the malignant osteosarcoma clone itself.110 Clinical 
trials of zoledronic acid in breast cancer have prolonged 
overall survival.111
The following four data sets are paradigmatic of our sug-
gested use of zoledronic acid in glioblastoma:
1) Rietkotter et al showed that zoledronic acid reduced 
viability of circulating monocytes and central nervous 
system microglia112 and microglia exposure to zoledronic 
acid in ex vivo brain slices also reduced invasion by 
breast cancer cells without affecting the breast cancer 
cells themselves.112
2) Indicative of our view of cancer generally as a systemic dis-
ease, Hiroshima et al showed that peritoneal macrophages 
from mice bearing flank-injected pancreatic tumor cells 
enhanced this cancer’s growth when in vitro and in vivo 
when injected into other tumor-bearing mice.113
3) Ohba et al showed that MCP-1-secreting osteosarcoma cells 
were blocked from secreting MCP-1 by zoledronic acid.110
4) In discussing the correlation between increased tumor-
infiltrated macrophages and poorer prognosis, Rogers 
and Holen presaged our views, stating in 2011, “Tumor 
cells communicate with the cells of their microenviron-
ment via a series of molecular and cellular interactions to 
aid their progression to a malignant state and ultimately 
their metastatic spread”. They reviewed data collected 
prior to 2011 supporting their contention that zoledronic 
acid exerted an anti-breast cancer effect by defeating 
MLC’s promotion of the malignant clone’s growth.114 
In this paper we make a similar argument in the setting 
of glioblastoma.
The MTZ trial
We are planning a pilot clinical trial of the MTZ Regimen 
in primary glioblastoma, using oral minocycline 100 mg 
three times daily, oral telmisartan 80 mg twice daily, and 
intravenous zoledronic acid 4 mg once every 28 days to be 
given starting postprimary resection, to run concurrent with 
standard radiation and temozolomide. The primary end points 
will be tolerability and time to progression, and secondary 
end point, overall survival.
Discussion
This paper recounts past research data establishing that nor-
mal host monocytes are pathologically recruited to and by 
the glioblastoma tumor. Glioblastomas synthesize and secrete 
MCP-1 that recruits these monocytes among other effects. 
Glioblastoma, like other tumors, is not simply a growing 
autonomous parasitic entity, although it does have elements 
of this. Glioblastoma is more accurately understood as a 
malignant clone that secretes cytokines and other hormone-
like molecules that signal to normal host cells and organs to 
support the malignant clone’s survival and growth. Glioblas-
toma is thus integrated into total body physiology.
Given that MCP-1 plays an important role in the destruc-
tive inflammatory process of nonalcoholic steatohepatitis,115 
we could consider MTZ Regimen or elements of this as part 
of its treatment.
Psychiatry also is intently interested in microglia–neuron 
interactions potentially modifiable by minocycline.116 
A single case report of minocycline 50 mg po twice daily 
stopping difficult-to-control seizures in a grade III glioma 
was interpreted as evidence of its anti-inflammatory effects.117 
Going on data and theory that glial activation contributes to 
pathophysiology of psychotic disorders, three studies, one 
from 2010 and two from 2014, independently confirmed 
that minocycline reduced the negative sign/symptom picture 
that is commonly seen as residue in otherwise well-treated, 
“schizophrenia”.118–120 “Schizophrenia” is mentioned in 
quotes because it is an outmoded term comprising a dozen 
different pathophysiological entities with prominent psycho-
sis that, as yet, remain unnamed.121
The malignant MCP-1-centered synergy between the 
glioblastoma cell and infiltrating microglia or circulating 
monocytes goes some of the way toward explaining the rar-
ity of metastases outside the central nervous system, even 
though circulating malignant glioblastoma cells have been 
easily demonstrated in human disease.122
It is standard military doctrine to destroy a pathway cru-
cial to the enemy along several points along that pathway. 
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Toward a noncytotoxic glioblastoma therapy
chances for the enemy to develop repairs, workarounds, or 
alternatives that can substitute for or reconstitute the blocked 
pathway. Destroying multiple points along a crucial pathway 
significantly impedes an enemy from doing this.
In reviewing the trophic and permissive function of brain 
microglia for breast cancer metastases Pukrop et al observed 
“inhibition of proinvasive microglia as a promising anti-
metastatic strategy”.123 We provided it here.
MCP-1-triggered hypoxia-related gene transcription and 
translation via a signal transducer and activator of transcrip-
tion 3 phosphorylation represents an intermediate step in 
pluripotent epiblast cells (outer embryonic layer destined to 
later differentiate into ectoderm and mesoderm layers).124 The 
potential importance of this in glioblastoma and other cancers 
is that MCP-1 has hypoxia-adapting signaling attributes to 
cells other than MLCs. In accord with these findings are those 
of Jung et al who found that minocycline inhibited hypoxia 
induction factor-1α transcription and translation.125
Baer et al recount details of a reciprocal feedback system 
between MLCs and tumor-associated new vessel formation, 
where “physical contact of macrophages with growing blood 
vessels coordinates vascular fusion of emerging sprouts”.126 
This feedback (feed-forward) system between MLCs and 
developing blood vessels is reminiscent of the feed-forward 
system of Schruefer et al who describe a vessel formation 
enhancing reciprocal relationship between centripetal-
migrating neutrophils and the developing tumor vessel 
neo-intima that was based on IL-8.31,127 We can expect inter-
ventions directed against both MLCs and neutrophils each to 
contribute to suppression of tumor neoangiogenesis.
Radiation of brain tissue during initial glioblastoma treat-
ment often results in memory or intellectual impairments of 
varying degree.128 As a potential added benefit, minocycline 
reduced memory impairment in radiated rats129 and might do 
so in brain-radiated glioblastoma patients.
As an added benefit of telmisartan, Januel et al showed 
empirically that those glioblastoma patients coincidentally 
taking angiotensin-blocking drugs or angiotensin-converting 
enzyme inhibitors have longer overall survival than those 
not on these antihypertensive drugs.130
Conclusion
Malignant cells co-opt normal cells and physiological sys-
tems to serve and enhance growth of the malignant clone/
clones. Glioblastoma, like other cancers, can be thought of 
as an organ system, actively and reciprocally interacting and 
coordinating with other organ systems of the body, includ-
ing the immune system. In this case, this collaboration has 
destructive consequences for the host, yet the elements of 
this pathologic relationship incorporate normal physiological 
systems and communication molecules such as MCP-1.
Current thinking in oncology is not oriented to considering 
a) the collective effects of drugs or b) effect on and treating 
contributions of nonmalignant helper cells of the body – in this 
case MLCs. We tend rather to think of individual effects of the 
various drugs in a mix. We now propose a paradigm shift to 
reflect reality more accurately. The reality is that glioblastoma 
like other cancers has a multiplicity of cross-covering growth 
paths, most of which must be addressed for successful treat-
ment. Malignant clone-directed treatments must be augmented 
by simultaneous different treatments directed at halting or lim-
iting the participation of normal host cells and organ systems 
that subserve and enhance growth of the malignant clone.
Our paper reviewed data showing that growth of glioblas-
toma cells is connected with and facilitated by surrounding 
normal microglia and other MLCs, abnormally recruited to 
and activated by the malignant clone. Our views are in accord 
with data and views of others. We offer the MTZ Regimen 
to defeat the role of MLCs that have been abnormally stimu-
lated by MCP-1.
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